Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN secukinumab mechanistic study in psoriatic arthritis
2015-004502-42Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in psoriatic arthritis (PsA), sponsored by University of Liverpool. Primary endpoint: Neutrophil phenotype and lifespan change in function over time. Started Jan 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-004502-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004502-42.